TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02718235

Intervention type: OTHER
Intervention: Overall survival
Description: Observation of overall and disease free survival

Intervention type: OTHER
Intervention: Overall survival
Description: Observation of overall and disease free survival

Intervention type: OTHER
Intervention: Overall survival
Description: Observation of overall and disease free survival
Study: NCT02863393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing exercise
Description: Through diaphragmatic breathing exercise to verify the impact of this item interventions on patients' metabolism indicators.
Study: NCT03908203

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Minimally invasive one-level lumbar deformity correction
Description: The study treatment represents modified technique of MIS TLIF: one level screws fixation using Wiltse approach at one side, the other side - percutaneously, one level decompression, correction of segmental deformity by performing vertebrotomy and then intervertebral fusion.
Study: NCT02886650

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermocoagulation
Description: Thermocoagulation During pre-surgical Invasive EEG Monitoring
Study: NCT01332214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2820
Description: Subcutaneous Injection in abdomen or Thigh

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection in abdomen or Thigh
Study: NCT03570073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitrification with GaviTM system
Description: Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
Study: NCT01393496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: red blood cell transfusion
Description: Implementation of liberal guidelines for red blood cell transfusions in extremely low birth weight infants

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: red blood cell transfusion
Description: Implementation of restrictive guidelines for red blood cell transfusions in extremely low birth weight infants
Study: NCT03368794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active treatment referral of opioid overdose survivors to long-term treatment
Description: Telephone alert and outreach for inclusion, assessment and intake into long-term evidence-based treatment of the substance use disorder.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Written information from ambulance staff to the patient about how to seek treatment. Patient is able to contact the research treatment facility through a specific phone number, making it possible to study treatment entry in the information-only control condition.
Study: NCT06495827

Intervention type: OTHER
Intervention: No different intenvention
Description: No different intenvention

Intervention type: OTHER
Intervention: No different intenvention
Description: No different intenvention
Study: NCT00548418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT05951140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usage of the PROTEIN-Application
Description: Participants were randomly distributed into 2 groups: (1) Start-Group used the developed Application and wereables to investigate the effect of this support. Participants used the devices and the App for 3 Months followed by a 6-Weeks time of only using wereables and no app, to be able to compare the effects of the Application. (2) The Wait-Group used wereables for 6 Weeks before adding the Protein-App for also 3 Months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usage of the PROTEIN-Application
Description: Participants were randomly distributed into 2 groups: (1) Start-Group used the developed Application and wereables to investigate the effect of this support. Participants used the devices and the App for 3 Months followed by a 6-Weeks time of only using wereables and no app, to be able to compare the effects of the Application. (2) The Wait-Group used wereables for 6 Weeks before adding the Protein-App for also 3 Months.
Study: NCT04248998

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet
Description: Cyclic, 5-day, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low protein diet every three weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet
Description: Cyclic, 5-day, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low protein diet every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg twice a day
Study: NCT00735917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT01338649

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright Light Treatment (Sun Ray Sunbox SB-558)
Description: Bright Light Treatment (Sun Ray Sunbox SB-558) using light intensity of 10,000 lux, administered during two 1 hour periods during the day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dim red light (Sun Ray Sunbox SB-558)
Description: Dim red light box administered during two 1 hour periods during the day using
Study: NCT00704730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules color and size-matched to XL184 capsules administered orally daily
Study: NCT01296659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy
Study: NCT04673513

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: In light of COVID-19 considerations, interventions are currently being provided via telehealth technology.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: In light of COVID-19 considerations, interventions are currently being provided via telehealth technology.
Study: NCT05906420

Intervention type: DIAGNOSTIC_TEST
Intervention: ASTRAL prognostic score
Description: ASTRAL prognostic score
Study: NCT03884374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused Breathing and Attention Training (BAT)
Description: Participants will receive mindfulness-based mental training regimen to independently practice mindfulness meditation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused Breathing and Attention Training (BAT)
Description: Participants will receive mindfulness-based mental training regimen to independently practice mindfulness meditation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Breathing and Attention Training (BAT)
Description: Standard BAT intervention will incorporate most of the general aspects of the Focused BAT intervention but without the specific instructions related to mindfully attending to the breath in a non-evaluative manner.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Breathing and Attention Training (BAT)
Description: Standard BAT intervention will incorporate most of the general aspects of the Focused BAT intervention but without the specific instructions related to mindfully attending to the breath in a non-evaluative manner.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: A Soterix 1x1 Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two bicarbon rubber electrodes encased in saline-soaked sponges

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: A Soterix 1x1 Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two bicarbon rubber electrodes encased in saline-soaked sponges

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Sham stimulation procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA (30s ramp up/down) of stimulation at the beginning of the session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Sham stimulation procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA (30s ramp up/down) of stimulation at the beginning of the session.
Study: NCT01679106

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAP catheter with Ropivicaine
Description: Patients will receive TAP catheter with continuous infusion of Ropivicaine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl IV PCA and placebo TAP catheter
Description: Patients will receive placebo TAP catheter with Fentanyl IV PCA.
Study: NCT02928380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Denture Adhesive
Description: Participants received a single application of test denture adhesive with a Flat Ribbon Nozzle as 3 Continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture which were placed in the mouth.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reference (Marketed) Denture Adhesive
Description: Participants received a single application of marketed denture adhesive with a flat ribbon nozzle as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture, which were placed in the mouth.
Study: NCT00292747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drotaverine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotaverine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drotaverine Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Placebo
Study: NCT02174783

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Patient will be provided with basic nutrition educational materials that outline principles of a healthy diet, including: moderation, portion control, increased intakes of fruits, vegetables and whole grains and reduced intakes of saturated fat, salt and sugar. Brief education will be provided by the hepatologist without dietitian referral.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Patient will receive verbal diet instruction from the dietitian or from the hepatologist who has received instruction from the dietitian on following the Mediterranean diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein-Sparing Modified Fast (PSMF)
Description: Patient will be referred to the dietitian for an appointment to discuss the PSMF plan.~Protein needs of 1.5 grams/kilogram will be calculated based on patient's actual body weight.~Patient will receive verbal instruction from the dietitian, as well as printed materials for reference at home. Dietitian will provide a list of allowed and prohibited foods as per Cleveland Clinic's PSMF diet standards.
Study: NCT00502528

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Peri-interventional

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BQ-123
Description: Peri-interventional
Study: NCT03943446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-018
Description: TAK-018 immediate-release tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-018
Description: TAK-018 immediate-release tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-018 Placebo
Description: TAK-018 placebo-matching tablets.
Study: NCT03055572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory Training with Essential Oils
Description: Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Essential oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
Study: NCT00653055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Tablets, 0.5 mg (2 x 0.5 mg dose),fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dostinex
Description: Tablets, 0.5 mg (2 x 0.5 mg dose), fasting
Study: NCT03055572

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olfactory Training with Pure Fragrance Oils
Description: Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Pure fragrance oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
Study: NCT03439111

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Lycium chinense Fruit Extract (LCF) capsules
Description: All dried water extracts and capsules of the Standardized Lycium chinense Fruit Extract (LCF) and Standardized Lycium chinense Fruit Extract (LCF)-matched placebo capsules used in the present study were manufactured and provided by the BIOMIX Company (Ilsan City, Korea).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standardized Lycium chinense Fruit Extract (LCF) capsules
Description: All dried water extracts and capsules of the Standardized Lycium chinense Fruit Extract (LCF) and Standardized Lycium chinense Fruit Extract (LCF)-matched placebo capsules used in the present study were manufactured and provided by the BIOMIX Company (Ilsan City, Korea).
Study: NCT03694054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care coordination tool
Description: Participants will be asked to enroll in the care coordination tool, a health information technology solution that integrates cross-sector data to enhance communication and improve quality of care and performance outcomes. Patients will also be asked to provide consent to allow the study team to access additional health information via the electronic health record.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care coordination tool
Description: Participants will be asked to enroll in the care coordination tool, a health information technology solution that integrates cross-sector data to enhance communication and improve quality of care and performance outcomes. Patients will also be asked to provide consent to allow the study team to access additional health information via the electronic health record.
Study: NCT01755312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication reminder
Description: Medication reminder
Study: NCT00873288

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care mailing intervention
Description: routine colposcopy reminder letter
Study: NCT03719807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol
Description: A physiotherapy rehabilitation protocol - comprising of pragmatic exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: No routine outpatient physiotherapy. Normal inpatient physiotherapy to match intervention group.
Study: NCT00873288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIS support mailing intervention
Description: Mailed reminder plus provider recommendation to call CIS and sample questions to ask
Study: NCT02980692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG1623 I
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG1623 II
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG1623 III
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG1623 IV
Description: injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: injection
Study: NCT03479216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex
Description: 10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: 10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.
Study: NCT02765503

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiotherapy
Description: External beam radiotherapy using megavoltage radiotherapy with radical intent.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: External beam radiotherapy using megavoltage radiotherapy with radical intent.
Study: NCT04019795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REVIAN 101
Description: The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 101 delivers 625 nm and 660 nm wavelengths of red light.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REVIAN 102
Description: The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 102 delivers 425 nm wavelength of blue light.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REVIAN 103
Description: The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 103 delivers 425 nm wavelength of blue light and 625 nm and 660 nm wavelengths of red light.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: REVIAN 100
Description: The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 100 contains LEDs that are not powered for light therapy
Study: NCT03649334

Intervention type: DRUG
Group type: OTHER
Intervention: ketamine-ketorolac
Description: The patient will receive ketamine 0.5mg.kg-1 + ketorolac 1mk.kg-1 in 2 ml syringe intramuscularly.

Intervention type: DRUG
Group type: OTHER
Intervention: fentanyl- ketorolac
Description: The patient will receive fentanyl 1.5ug.kg-1 + ketorolac 1 mg.kg-1 in 2ml syringe intramuscularly
Study: NCT02521298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Study: NCT03952208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Testing
Description: A comprehensive assessment of neuropsychometric measures to evaluate cognitive functioning.
Study: NCT04790123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of autologous freshly collected adipose tissue
Description: injection of fresh autologous fat, previously lipoaspirates from the patient's abdomen and centrifugated, into the fistulous tract, after curettage and closure of the internal opening.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: curettage and closure of the internal orifice of the anal fistula and simulated intervention in the abdomen.
Study: NCT01946360

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Methacetin Breath Test in ACLF and ALF patients
Description: Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
Study: NCT03792087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SmofKabiven Peripheral
Description: Total Parenteral Nutrition
Study: NCT02521298

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortico-Steroid Injection. Depomedrol 40mg/1ml.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Study: NCT02169804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 25 mg
Study: NCT04169113

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 - Opiate Tablets post Hip Arthroscopy
Description: Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 - Opiate Tablets post Hip Arthroscopy
Description: Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
Study: NCT03823040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxiconazole Nitrate Cream 1%
Description: Tinox® group was treated with oxiconazole nitrate cream 1 % . Treatment was performed by rubbing the cream twice daily for two/ four weeks according to different types of tinea.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxiconazole nitrate SLNs loaded gel.
Description: Oxiconazole nitrate SLNs loaded gel group was treated with oxiconazole nitrate SLNs loaded gel.Treatment was performed by rubbing the gel twice daily for two/ four weeks according to different types of tinea.
Study: NCT03792087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hospital compounded emulsion
Description: Total Parenteral Nutrition